8-K current report · filed Sep 11, 2026

ACADIA PHARMACEUTICALS INC (ACAD) 8-K Current Report: September 11, 2026

Item 8.01Item EX-99.1Item EX-99.2ACAD overview

Short answer

ACADIA PHARMACEUTICALS INC (ACAD) filed an 8-K current report with the SEC on September 11, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Court preliminary approval of derivative-action settlement in Kanner et al. v. Biggar et al.

ACADIA PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Court preliminary approval of derivative-action settlement in Kanner et al. v. Biggar et al.
  • ACADIA required to publish settlement notice and stipulation under the Court’s order
  • Final settlement status remains subject to subsequent court approval
  • Investors should review Exhibits 99.1 and 99.2 for settlement terms and potential company obligations

Item EX-99.1 · Exhibit EX-99.1

  • Proposed derivative settlement requires governance reforms maintained for at least four years
  • Defendants to pay $1.5 million in attorneys’ fees and expenses, subject to court approval
  • No direct shareholder payout or common fund; settlement resolves claims without admissions of wrongdoing
  • Settlement hearing scheduled January 13, 2027, with objections due December 23, 2026
  • Approval would release related derivative claims and end associated governance litigation for current shareholders

Item EX-99.2 · Exhibit EX-99.2

  • Derivative litigation settlement addresses alleged fiduciary breaches, misleading pimavanserin sNDA disclosures and insider stock sales
  • Acadia to implement corporate-governance reforms for at least four years, replacing litigation-based recovery with operational controls
  • $1.5 million attorneys’ fee and expense payment, subject to court approval, creating a direct corporate cash cost
  • Settlement remains contingent on court approval, with claims released and derivative action dismissed with prejudice after final approval
  • Related securities class action and opt-out action remain excluded from the release and pending, preserving separate litigation exposure

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ACADIA PHARMACEUTICALS INC 8-K filings

Get the next ACAD 8-K as it lands

Follow ACAD for push alerts, or ask the research agent what this filing means.